LOWELL, Mass., June 1, 2017 /PRNewswire/ — Arthromeda, Inc., a developer of intelligent orthopedic navigation systems, closed its Series D financing to take the ArthroSight-PS Hip Alignment System (ArthroSight-PS) through commercial regulatory approvals and clinical validation. This was achieved following a series of successful cadaver labs conducted by surgeon Daniel Ward, MD (New England Baptist Hospital, Boston, MA) at the Cincinnati Children’s Hospital and Medical Center translational research lab (Cincinnati, OH). The cadaveric studies confirmed that the ArthroSight- PS is an intuitive All-in-One system for accurate and precise implant positioning, providing real-time position angles (inclination and anteversion), leg length and femoral offset difference measurements. Videos from the labs can be found in Arthromeda’s newly released clinician and patient focused website www.arthromeda.com.
Accurate hip implant positioning is an extremely important factor for patients, physicians, regulators and device companies. In recent years, the number of hip surgeries has skyrocketed with increasing numbers of younger adults getting the procedure according to popular press reports. Over the 10 years of the study, the number of procedures more than doubled, from 138,700 in 2000 to 310,800 in 2010. The number grew by 92 percent, to 80,000, among those aged 75 and older. It jumped by 205 percent in those aged 45 to 54, to 51,900. Due to the aging baby boomer population, the magnitude of the problem is projected to increase dramatically – doubling by 2030.
“Patient-specific solutions in surgery that are individualized to patients at an affordable cost are important. I am delighted to support Arthromeda in its game-changing mission to help patients undergoing hip arthroplasty experience superior outcomes,” commented Edgar D. Jannotta, Jr., Arthromeda Director and lead investor.
Elsa Chi Abruzzo, RAC, FRAPS, chief operating officer of Arthromeda, commented, “I am grateful to our founder and executive chairman, Mr. PJ Anand, for his clear strategic vision and leadership. I also appreciate the technical insight of our cofounder and Chief Technical Officer, Mehran Aghazadeh, MD. We are excited to execute on the next phase of development of this elegant solution for real-time, accurate, acetabular cup positioning and leg length and femoral offset adjustments, without the expensive capital investments or increased procedure time associated with robotic and imaged-based systems.”
Foley Hoag LLP, led by Life Sciences Practice chair Jeffrey Quillen and Patrick Connolly, represented Arthromeda in the financing. Mr. Quillen & Connolly have represented Arthromeda since its founding in 2011.
About Arthromeda, Inc.
Founded in 2011, Arthromeda, Inc. is a private medical device company focused on developing intuitive, real-time, sensor based, intelligent technologies to improve surgical outcomes for patients undergoing joint replacement procedures. As part of its extensive patent protected intellectual property portfolio, Arthromeda has created two distinct, yet complimentary, technology platforms to reduce operating room time, improve patient outcomes, and reduce the cost burden associated with early implant failure. More information can be found at www.arthromeda.com
Contact: Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701 jennifer@cwcomm.org
Paxeon Reconstruction, a manufacturer of best-in-class orthopedic products including derivative and emerging products, announces the promotion of Kyle Sineath to President. Prior to this appointment, Mr. Sineath served as Vice President of Global Sales for Paxeon. Mr. Sineath joined Paxeon after 10 years in the medical technology and orthopaedics industry, where he held a number of senior level leadership roles at Amedica and most recently, Vice President of Sales for NuTech Medical. Mr. Sineath holds a duel Bachelor of Science from the University of Pikeville.
“The orthopedics market has changed dramatically over the past 10 years and I am thrilled to be in a position to bring new products and creative ideas that further assist our surgeons deliver the best possible outcomes for patients around the world.” Said Mr. Sineath.
In addition to this appointment, Mr. Sineath has been asked to participate as a panelist at the upcoming Becker’s 15th Annual Spine, Orthopedic and Pain Management-Driven ASC Conference + The Future of Spine on June 22-24, 2017 in Chicago, IL.
With keynote speakers Andrew Hayek (Chief Executive Officer of Optum Health and Surgical Care Affiliates), Michael Kasper (Chief Executive Officer of DuPage Medical), Lou Dobbs (Fox News) and Marcus Allen (Former NFL Running Back and Member of the NFL Hall of Fame), this conference includes more than 1,100 Attendees at this World-class ASC Event Focused on Orthopedics, Spine and Pain.
In the session titled “Investing in Early Stage Spine and Device Companies – Smart? Dumb? and Practical Advice”, Mr. Sineath will be joined by President and CEO of AngelMD, Tobin Arthur, as well as President and CEO of Life Spine, Michael Butler. The session will be moderated by John Harig, JD.
______
About Paxeon Reconstruction
Paxeon Reconstruction builds best-in-class orthopaedic products, including derivative and emerging products. We collaborate with hospitals, health systems and physicians to create alignment and utilization of value-based solutions combined with efficiency models for today’s changing healthcare environment. Paxeon Reconstruction offer the world’s most comprehensive portfolio of orthopaedic products and services for joint reconstruction. Paxeon Reconstruction has a celebrated clinical history, and has evolved to meet the needs of the changing orthopaedics marketplace. The history that weaves the fabric of the Paxeon Reconstruction is one that is rich with innovation and demonstrates sustained leadership in an ever-changing landscape of patient and professional needs.
The orthopedic industry is changing faster than ever before. Whether you’re a surgeon, sales rep or orthopedic patient, much of the impact is less than positive. It seems that the industry is piling on the sales rep in an effort to marginalize and some might say eliminate the rep altogether. I recently read a headline about HCA’s record quarterly profits topping $980 MILLION. Keep in mind that this was Q4, 2016 at a time when hospitals are crying poor while fighting orthopedic companies on pricing like never before. Gone are the days where it was customary to assess a 3% price increase tied to the Consumer Price Index (CPI) each year. Now as a rule, hospitals and GPO’s are forcing prices to new lows year over year and even seem willing to sacrifice the presence of the rep in the operating room. It is impossible to argue the point that the orthopedic sales rep is being marginalized. In recent years, they have been told by various constituents that they are a “non-essential” part of the healthcare continuum. In an effort to increase profits, not only are these hospitals and GPO’s fighting to bring down prices, but they also seem to be fighting over the remaining piece of the pie belonging to the sales rep by way of confiscating their commissions. But are sales reps expendable? Do they only add cost to the continuum as some suggest?
If reps are eliminated from the picture, who will step in to bear the burden of support that surgeons are accustomed to receiving from their sales reps? Are surgeons going to be expected to hire P.A.’s to fill in the void of what the reps currently do? Does anyone really grasp the full picture of what the orthopedic rep does and value they bring to the healthcare system? Let me try to give you a former sales rep’s perspective on the value of the orthopedic sales rep.
A historical perspective
When I started as a sales rep for Zimmer in the orthopedic industry 30 years ago, it was evident to me that being a rep afforded me the privilege of being an integral part of the surgical team to ensure the most optimal surgical outcomes for the orthopedic patient. There was a level of trust, camaraderie and appreciation that made the role extremely rewarding. Reps like myself felt appreciated because it was evident that surgical teams wanted us in the room during cases because of the unique value we brought to the case. Ours was a special role of supporting both the surgeons as well as the hospital’s support staff. Whether we were an extra set of hands to hold the patient’s leg during prep or opening that sterile peel pack when someone dropped a disposable suction tip when the circulator was preoccupied, we stepped in to do whatever we could to keep the case progressing without a delay. Having a rep in the room was an obvious value to all because we possessed a unique perspective and skill set. We were the ones with experience in those unfortunate scenarios when things did not go just like they are supposed to in the technical video. On the infrequent occasion of a surgical complication, the reps are typically leaned on for their expertise. They help the surgeon troubleshoot during the procedure to bring about an optimal successful outcome. In many cases, the rep is the person with the most diverse experience with the products and procedure even if only by observation. Countless times, I was leaned on by the surgeon to solve a complex challenge that arose either out of some unexpected pathology or a complication. I was the one who witnessed thousands of procedures encountering far more complications and variables than the scrub tech, assistant or the surgeon. I was the one with the broadest experience to walk them through how to resolve it in such a way as to bring about the best result. In extreme cases, observers said that watching a good sales rep in surgery was often like seeing the sales rep “conduct surgery through remote control.” I was accustomed to it and considered it a privilege to ensure my surgeon’s patient had the best possible result. This kind of support is an everyday routine for many sales reps in O.R.s around the world. Before my time, I heard stories from reps that actually scrubbed in and held retractors, and in some cases doing far more of the procedure than anyone would expect until finally someone got into deep trouble. There was a book written about it called, “Salesman Surgeon” that recounts a situation where the surgeon was not even in the room when some cases were being done.
We are a long way away from that, and that is a very good thing. However, there are very real benefits as a result of having reps participate in the O.R. I am convinced that there are profound benefits to the hospital, surgeon, staff and patient.
1. Better Patient Outcomes
2. Time Savings
3. Cost Savings
These merely represent the value of the rep in the room. However, there is great value to healthcare beyond having an orthopedic sales rep present during surgery. In fact, it is what leads up to the surgical theater that is often overlooked and without a talented rep, a void will be created that must be filled by someone. It was always gratifying to me the appreciation that I received from nurses and administrators. However, I remember showing up to sell in my new territory at an O.R. in Lancaster, CA to introduce myself as the new Zimmer rep back in 1989. I entered the O.R., while staying behind the line, and asked the gal at the desk if I could speak with the O.R. Supervisor. She gave me a long up and down look then proceeded to speak into the microphone to the overhead intercom to announce my arrival. “Jennifer, there’s a gentleman with tassels on his shoes at the desk waiting to see you.” That is how some people see reps. Just well dressed people who waltz in and expect to have the red carpet to sell people stuff. In reality, reps spend a ton of time meeting with surgeons to help them with preoperative planning, reviewing x-rays to ensure that they are ready for anything when the patient is under anesthesia. It is the job of a rep to be 100% certain that you have everything you need for the case which may require flying equipment in from cross country, but not having it is never an option.
It seems overlooked that sales reps, especially those who cover trauma, are on the clock 24/7 in support of their surgeon and hospital clients. It might seem like no big deal to those who don’t understand the implications, but imagine for a moment that you are a sales rep and you have 20 surgeons you support, each with their own individual schedule and demands. It is a balancing act like no other to support the needs of these surgeons and their patients. Not showing up or having the equipment ready for a case is never an option, and certainly would result in risking losing business and tarnishing your reputation. There are always competitors standing in lurch waiting for someone to mess up. I always said that for every surgeon who uses a product, there is a rep “on deck” waiting for their chance to save the day when you screw up.
Another reality for many reps is never taking a family vacation that wasn’t somehow tied to a business event. In my day, not only did I have to pay my own way but also those of some of my surgeon customers and their families. It wasn’t so much about getting new business as it was about protecting your business. The expectation was that since they used my products and I benefitted from it, I would cover the major expenses of their trip to get CME credits. The risk was that if I did not, one of my competitors would entice them to go to one of their meetings and they may come home and switch.
The industry has changed in some positive ways as well. When I was the Zimmer rep, I covered everything from Recon to Trauma. This meant that I could easily be in surgery all day on Monday, get a trauma case in the evening requiring me to be there all night, and not make it home before my 7:30AM case the next morning. When I was on call, I could be at dinner or a movie with my wife and suddenly have to run her home to run sets and cover a case. Sunday mornings looked like driving to church in separate cars in case the pager went off and I had to leave on the spur of the moment.
The point I’m making is that in a very real sense, many sales reps have the insane schedule of a surgeon with many similar time demands, and yet without some of the upside. It is also the rep that enables surgeons to make quick decisions about treatment of a patient and they know their rep will take care of getting everything they need to fix the patient. It may be as simple as calling the office and having it delivered or more complex as having to drive across town to borrow it from another hospital or distributor, or even times when you have to contact someone out of state and have equipment flown cargo on a commercial airline to get there in time. The reality is that most of the stressful things that happen never see the light of day and no one in the hospital is aware of the extreme measures taken in order to see to it that the patient got the very best treatment.
It is unclear to me who will be there to step into the gap and support the orthopedic surgeon if the rep is tossed to the side. I think we always expected that over time the market would force out the more skilled and experienced orthopedic reps in favor of cheap labor, similar to a pharma rep. Our saving grace was always that they didn’t like to work that hard. Perhaps the time has come that the market will shift the reps support responsibilities on to the surgeons who will undoubtedly need to hire someone to support them. Maybe the market simply needs to see what it looks like to force the best and brightest out and see the impact on the surgical teams. One thing is for sure, the market seems to behave like they see reps as unnecessary. Time will tell.
Drue De Angelis
CEO, Surg.io LLC
Surg.io is the total orthopedic distributor/rep solution to go from working “in” your business, to working “on” it. A simple software solution that adapts to your workflow enabling greater communication, accuracy and efficiency. Surg.io saves time and money. It’s like having an extra person on the team. /Surg.io
VIENNA, May 31, 2017 /PRNewswire/ — DePuy Synthes*, part of the Johnson & Johnson Family of Companies, today announced new ATTUNE® Knee implant survivorship data based on an independent analysis of 10,605 ATTUNE Knee implantations, showing that the cumulative revision rate for the ATTUNE Knee is 1.3% at four years (98.7% implant survivorship at four years), comparing favorably to the 1.9% cumulative revision rate (98.1% implant survivorship at four years) for the overall class of total knee replacement.1
Of the 10,605 ATTUNE Knees included in the analysis from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR), 46 required revision. Based on a separate analysis, the report concluded that 63 ATTUNE Knee revisions would be expected at four years – a difference that was statistically significant (p<0.05).1 The expected number of ATTUNE Knee revisions was calculated by the NJR based on duration of implantation, age group, gender and indications.
DePuy Synthes announced the four-year data in Vienna, coinciding with the 18th European Federation of the National Associations of Orthopaedics and Traumatology (EFORT) Congress. The full analysis, including a breakdown of the reasons for revision, is available on ATTUNEevidence.com and can be accessed here.
“This most recent analysis adds to the body of evidence on the positive performance of the ATTUNE Knee,” said Joshua Bridgens, DePuy Synthes Franchise Medical Director. “The information and data in this analysis, such as reasons for revision and preliminary findings on patient-reported outcomes, continue to validate the design principles and our expectations for the clinical performance of the ATTUNE Knee.”
NJR publishes an annual report including 1, 3 and 5-year outcome data; however, additional survivorship data is now also available more frequently to manufacturers who subscribe to the NJR’s Implant Summary Report service.
DePuy Synthes is committed to the continued evaluation of outcomes through its comprehensive ATTUNE Knee Evidence Generation Program that, in addition to national joint registries, gathers information from investigator-initiated studies, independent studies and company initiated studies. ATTUNE Knee clinical evidence to date is available on ATTUNEevidence.com.
About DePuy Synthes
DePuy Synthes, part of the Johnson & Johnson Family of Companies, provides one of the most comprehensive portfolios of orthopaedic solutions in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, neurological, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.
*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.
DSUS/JRC/0517/2149 May 2017
References
1National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. Implant Summary Report for DePuy ATTUNE CR and ATTUNE PS. NJR Database extract April 7, 2017, pages 1-17. Licensed for use until April 19, 2018. Available at www.attuneevidence.com.
Data Source
The data used for this analysis was obtained from the NJR Supplier Feedback System. The Healthcare Quality Improvement Partnership (“HQIP”) and/or the National Joint Registry (“NJR”) take no responsibility for the accuracy, currency, reliability and correctness of any data used or referred to in this report, nor for the accuracy, currency, reliability and correctness of links or references to other information sources, and disclaims all warranties in relation to such data, links and references to the maximum extent permitted by legislation.
GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, is pleased to announce that the first surgeries using the new Truliant® Knee System were performed yesterday. Truliant, which recently received 510(k) clearance from the U.S. Food and Drug Administration, offers a comprehensive portfolio of implants and instrumentation designed to help surgeons address the remaining clinical challenges of total knee replacement.
Craig Morrison, MD, of the Southern Joint Replacement Institute in Nashville, Tenn., and Michael Dayton, MD, from the University of Colorado in Denver, Colo. were the first surgeons to use the new knee system. According to Dr. Dayton, “The Truliant system has the advantage of being very user-friendly from the standpoint of ergonomic instrumentation. It should allow me to more accurately size, balance and efficiently perform the surgeries.”
“The Truliant system is intuitive,” Dr. Morrison said. “What I saw today is that you put the instrument in a surgeon’s hand, and they know what to do with it right away. I think the competitive advantage of this system is going to be how easily Truliant accommodates a surgeon’s preferred workflow.”
Designed with the ultimate surgical experience in mind, the Truliant Knee System is a high-performance, comprehensive platform that addresses the clinical challenges in primary and revision total knee replacement. Leveraging Exactech’s core principles, Truliant applies advanced design philosophies and surgical technologies to help surgeons deliver clinical outcomes reproducibly case after case.
According to Exactech’s Vice President of Knee Marketing Joseph Pizzurro, “With the number of knee arthroplasty surgeries on the rise, there is a market and clinical need for a system that offers enhanced efficiency and overall reproducibility. Based on input from a wide array of surgeons, Exactech’s design team of engineers and surgeon consultants converged to develop a modern, fully comprehensive knee system that offers a broad range of implants, intuitive instrumentation and computer-assisted technology to accommodate a variety of surgical approaches and philosophies. We are thrilled to introduce Truliant to the marketplace.”
Surgeons cite Exactech’s collaborative culture as a key to the new knee system’s intuitive design. “The people at Exactech are always leaning forward and engaging the surgeons,” said Ronald Hillock, MD, an orthopaedic surgeon in Las Vegas, Nev. “They have been very receptive to feedback, and I’ve always been impressed with the depth of their interest, from the top down. Everybody is in tune with designing a product that will give the best outcomes. It is engrained in their culture and it definitely comes through the products. Truliant is a prime example.”
Truliant is in pilot launch with a group of U.S. surgeons. Full market availability is expected in the United States during 2018.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
Contacts
Investor contacts:
Exactech
Jody Phillips, 352-377-1140
Executive Vice President of Finance & Chief Financial Officer
or
Hawk Associates
Julie Marshall or Frank Hawkins, 305-451-1888 EXAC@hawkassociates.com
or
Media contact:
Exactech
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication
QUEBEC CITY, QUEBEC, CANADA, May 24, 2017 /EINPresswire.com/ — Bodycad announced today that it has received product notification confirmation from the Belgian Federal Agency for Medicines and Health Products in Brussels, the legislative capital for the European Union, for its Bodycad Unicompartmental Knee System. This enables Bodycad to commercially launch this truly personalized orthopaedic restoration within the European Union in accordance with EU Medical Device Directive for custom devices. Bodycad is the first Canadian company to receive EU product notification confirmation for a joint reconstruction implant system.
Bodycad’s revolutionary Unicompartmental Knee System is designed to optimize personalized restoration of the patient’s unique anatomical features and kinematics. The system is based on proprietary 3D rendering of medical images of the patient’s anatomy. The restoration is delivered as a “procedure in a box” that completely revolutionizes the way orthopaedic implant and instrument applications are delivered and utilized in the operating room environment.
“The personalized restoration is created only after proper acquisition of data from the patient on an individualized level,” says Etienne Belzile, MD, orthopaedic surgeon and assistant professor at Laval University. “The benefit of personalized restoration is the possibility of a better fit to the individual, less trauma to the soft tissue, and potentially a faster recovery overall.”
Bodycad uses proprietary imaging algorithms to rapidly produce a precise 3D image of the patient’s knee. Its suite of Personalized Restoration Software enables a seamless integration of the image to implant process called the PREP (personalized restoration evaluation process). The efficient and rapid process is designed to increase patient satisfaction, improve manufacturing precision while improving economic quality metrics.
“Our proprietary software is based on 20 years of research in anthropometric data and is the first CAD/CAM software specifically developed for the personalization of orthopaedic implant and instrument design,” says Jean Robichaud, founder and CEO of Bodycad. “I am delighted to have European product notification confirmation to bring this important technological advancement to market. Our goal is to transform the way surgeons, patients and insurers think about the potential of mass customization to optimize patient care.”
About Bodycad
Bodycad is a Quebec City-based developer and manufacturer of personalized orthopaedics. Its personalized restorations offer patients a high level of conformity to their unique anatomy, with the potential for greater comfort, fit and durability that make the pursuit of orthopaedic perfection possible. Learn more at www.bodycad.com.
SOMERVILLE, N.J., May 24, 2017 /PRNewswire/ — Ethicon* announced the results of two economic analyses demonstrating that the DERMABOND® PRINEO® Skin Closure system, a product that combines a topical skin adhesive with a self-adhering patch, is associated with improved patient outcomes and lower healthcare costs for hospitals. Both studies are being presented at the International Society for Pharmacoeconomics and Outcomes Research’s 22nd Annual International Meeting this week.
The first study, Comparison of Economic and Clinical Outcomes between the DERMABOND® PRINEO® Skin Closure System and Skin Staples in Patients Undergoing Knee Replacement in Real World Clinical Practice,1 found that the DERMABOND PRINEO System is associated with improved outcomes for patients receiving total knee arthroplasty (TKA) when compared to skin staples. The findings are based on a retrospective analysis of 1,942 TKA procedures using the Premier Perspective® Hospital Database. Specifically, the DERMABOND PRINEO System was associated with a statistically significant reduction in readmission rates at 30, 60 & 90 days, a reduction in length of hospital stay and a lower probability of being discharged to a skilled nursing facility (SNF). The analysis showed that the 30-day readmission rate for the DERMABOND PRINEO System group was 1.8%, compared to 4.4% for the skin staple group. The costs of 30 day readmissions for TKA have been estimated to be $12,839.2 The DERMABOND PRINEO System was also associated with a 12% reduction in length of hospital stay and a 31% reduction in discharge to a SNF or other non-home setting, which could lead to savings in the acute and post-acute setting.
The second study, A U.S. Hospital Budget Impact Analysis of a Skin Closure System Compared with Standard of Care in Hip and Knee Arthroplasty, estimates the 90-day cost impact of the DERMABOND PRINEO System compared to other wound closure methods for hip and knee arthroplasty from a U.S. provider perspective.3 The analysis showed that the use of the DERMABOND PRINEO System DERMABOND PRINEO System in hip and knee arthroplasty may achieve cost savings that could translate into an annual hospital budgetary savings ranging from $28,349 to $39,809 when assuming 500 arthroplasties.3 The predicted cost savings was driven by reductions in dressing materials and post-operative healthcare visits when the DERMABOND PRINEO System is utilized.
“Ethicon is committed to bringing to market innovative products that are designed to provide improved outcomes for patients and enable our customers to provide the best care for their patients,” says Nefertiti Greene, Vice President, Global Wound Closure and Repair Platform Leader at Ethicon. “The DERMABOND PRINEO System has been shown by this research to be an excellent approach to wound closure.”
Reducing the length of a patient’s hospital stay can lead to reduced costs and may also lower the chances of contracting an infection.4In addition, reducing readmissions can prevent hospitals from being penalized for readmission rates above the national average for TKA.5 The reductions in health care resource utilization demonstrated in these studies are important for hospital systems and health care professionals particularly those who are part of or are considering episode-based payments where both acute and post-acute costs are combined into one payment.
Several benefits associated with the DERMABOND PRINEO System may explain the findings. The product provides significantly greater skin holding strength than skin staples and subcuticular suture,6+ and acts as a barrier to microbial penetration against organisms commonly associated with surgical site infection.7 The DERMABOND PRINEO System requires no postsurgical dressings which may mean easier self-care and greater self-confidence for patients.7 Also, if directed by their healthcare professional, patients can shower immediately after surgery7 which could lead to a higher level of patient satisfaction.
About Ethicon
From creating the first sutures to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Medical Devices Companies, has made significant contributions to surgery for more than 60 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world’s most pressing health care issues, and improve and save more lives. Through Ethicon’s surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treating serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Learn more at www.ethicon.com, and follow us on Twitter @Ethicon.
*Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates Ethicon, Inc. is the legal manufacturer of the DERMABOND® PRINEO® Skin Closure system. All other trademarks are the property of their respective owners.
+In an ex vivo study, more load in N was required to create a 3-mm gap between skin edges approximated with DERMABOND PRINEO System (22 cm) than with subcuticular 4-0 MONOCRYL® (poliglecaprone 25) Suture or PROXIMATE® Ethicon Endo-Surgery skin staples (P<.001).
073076-170517
1 Johnston S, Sutton N. Comparison of Economic and Clinical Outcomes between the Dermabond® Prineo® Skin Closure System and Skin Staples in Patients Undergoing Knee Replacement in Real World Clinical Practice. Poster Presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA. 2 HCUP Statistical Briefs website. Available at: https://www.hcup-us.ahrq.gov/reports/statbriefs/sbtopic.jsp. Accessed May 17, 2017 3 Sadik, K, Flener J, Gargiulo J, Graves M, Nunley, R Post, Z, Wurzelbacher, Sutton, N, Hogan, Hollman, S, Ferko, N. A U.S. Hospital Budget Impact Analysis of a Skin Closure System Compared with Standard of Care in Hip and Knee Arthroplasty. Poster Presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA. 4 Hassan M, Tuckman HP, Patrick RH, Kountz DS, Kohn JL. Hospital length of stay and probability of acquiring infection. International Journal of Pharmaceutical and Healthcare Marketing. 2010;4(4):324-338. 5 Centers for Medicare & Medicaid Services Readmissions Reduction Program (HRRP) https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html. Accessed May 17, 2017. 6 Data on file, Ethicon, Inc.: Kumar A. AST-2012- 0290. Completion Report: Study to compare the tissue holding strength of PRINEO Skin Closure System with conventional wound closure techniques. 2012. 7 Data on file. Ethicon, Inc. Dermabond Prineo System Master Claims Matrix.
LONG BEACH, Calif., May 24, 2017 /PRNewswire-USNewswire/ — The MemorialCare Joint Replacement Center at Long Beach Memorial is the first hospital in Long Beach and North Orange County to offer Stryker’s robotic-arm assisted total knee application for use with its Mako System – and now has successfully performed its first total knee replacement case in that region using this new technology. This latest advancement in joint replacement surgery transforms the way total knee replacements are performed.
Total knee replacements in the United States are expected to increase 673 percent by 2030,1 yet studies have shown that approximately 30 percent of patients are dissatisfied after conventional surgery.2 Mako Total Knee combines Stryker’s advanced robotic technology with its clinically proven GetAroundKnee (Triathlon Total Knee System), which enabled surgeons to have a more predictable surgical experience with increased accuracy during laboratory testing.3
“Mako is changing the way joint replacement surgeries are performed by providing each patient with a personalized surgical experience based on their specific diagnosis and anatomy,” said Andrew Wassef, M.D., medical director, MemorialCare Joint Replacement Center, Long Beach Memorial. “Using a virtual 3D model, the Mako System allows surgeons to create each patient’s surgical plan pre-operatively before entering the operating room. During surgery, the surgeon can validate that plan and make any necessary adjustments while guiding the robotic-arm to execute that plan. It’s exciting to be able to offer this transformative technology across the joint replacement service line to perform total knee, total hip and partial knee replacements.”
The Mako Total Knee application is a knee replacement treatment option designed to relieve the pain caused by joint degeneration due to osteoarthritis. Through CT-based 3D modeling of bone anatomy, surgeons can use the Mako System to create a personalized surgical plan and identify the implant size, orientation and alignment based on each patient’s unique anatomy. The Mako System also enables surgeons to virtually modify the surgical plan intra-operatively and assists the surgeon in executing bone resections.
“We are proud to be the first hospital to offer this highly advanced robotic technology in our area,” said Tamra Kaplan, PharmD, chief operating officer, Long Beach Memorial. “This addition to our orthopaedic service line further demonstrates our commitment to provide the community with outstanding healthcare.”
About the MemorialCare Joint Replacement Center at Long Beach Memorial:
Long Beach Memorial is lauded for superior clinical quality outcomes and has been listed on U.S. News & World Report’s America’s Best Hospitals since the annual rankings began. In this year’s results, Long Beach Memorial received “high performance” rankings in nine clinical specialty areas, including Hip Replacement, Knee Replacement and Orthopedics. It also is among a small percentage of U.S. hospitals consistently recognized for outstanding dedication to patient safety by maintaining a top “A” grade in eight of nine Leapfrog Group Hospital Safety Score evaluations for its ability to prevent errors, injuries, accidents and infections.
JRC specializes in a rapid rehabilitation program – where patients walk the same day of surgery – resulting in a shorter hospital stay – average hospital stay is zero to two days. The JRC features a dedicated unit for joint replacement patients with 15 private rooms, a joint care coordinator to help patients navigate through the program, patient education before and after surgery and “rehab coaches” to provide support as patients take their first steps toward an active lifestyle.
1. Kurtz AAOS. Total knee and hip replacement projections 2030. www.prnewswire.com/news-releases/total-knee and-hip-replacement-surgery projections-show-meteoric-rise-by-2030-55519727.html. Accessed July 4, 2016. 2. Christiaan Keurentjes J, Fiocco M, So-Osman C, et al. Patients with severe radiographic osteoarthritis have better prognosis in physical functioning after hip and knee replacement: a cohort-study. PLOS One. 2013; 8(4): 1-8. 3. Hampp EL, Scholl LY, Prieto M, Chang T, Abbasi AZ, Bhowmik-Stoker M, Otto JK, Jacofsky DJ, Mont MA. “Accuracy Assessment of Robotic and Manual TKA in a Cadaveric Model.” Robotic-arm assisted total knee arthroplasty demonstrated greater accuracy to plan compared to manual technique. ORS 2017 Annual Meeting. San Diego. Poster No.2412.
IRVINE, Calif., May 23, 2017 /PRNewswire/ — United Orthopedic Corporation (UOC), a leading international designer, manufacturer and distributor of innovative orthopedic implants and instruments, today announced the launch of a primary total knee arthroplasty (TKA) trial. Entitled “Prospective Post Approval Clinical Follow-Up Study of the Commercially Available U2 Knee™ System – ‘U Propel Study’,” the trial recently enrolled its first patient. This prospective, single arm, multi-center, post-market study will evaluate the short- and long-term clinical performance, and implant survivorship of the commercially available U2 Knee™ System in subjects receiving primary TKA.
“We were extremely confident with the execution and success of the first U2 Knee System replacement,” said David Cashen, MD, principal study investigator and practicing orthopedic surgeon at Coastal Orthopedics in Bradenton, Fla. “One day after surgery our patient is ambulating independently, performing a straight leg raise and confident to return home with only mild discomfort. We look forward to monitoring her recovery through our research.”
The U-Propel study will enroll up to 200 patients. Patients will participate in baseline, pre-discharge, six-week, three, six and 12-month, as well as annual follow-up visits for up to five years. The study’s primary endpoint is implant survivorship. The secondary endpoints are Knee Society Score; radiographic success; subject satisfaction; KOOS, Jr.; EQ-5D and operative characteristics. The expected duration of the study is seven years.
“For more than two decades, our company has been engaged in helping orthopedic surgeons deliver high-quality care to their patients, providing them with innovative products designed to improve patient health and satisfaction,” said Calvin Lin, President of United Orthopedic Corporation USA. “The U-Propel study underscores our continued commitment to orthopedic care, building upon our foundation of research that demonstrates the value of our solutions.”
Outcomes from the U-Propel study will be analyzed and published in three phases as follows: after all enrolled patients have completed their six-week follow-up; at the two-year follow-up mark; and at the conclusion of the study. In addition to Dr. Cashen and the team of surgeons at Coastal Orthopedics, George Markovich, MD, is also an orthopedic surgeon and study investigator. Dr. Markovich is from the Institute for Orthopaedic Surgery and Sports Medicine in Fort Myers, Fla.
Osteoarthritis is a common disease of the aging demographic and a leading cause of disability, with the incidence of knee osteoarthritis rising with the increasing average age of the general population.1 Approximately 10 percent of people aged over 55 years have painful disabling knee osteoarthritis, of whom one quarter are severely disabled.1 TKA is one of the treatment options available to sufferers of knee osteoarthritis.
UOC is actively recruiting qualified surgeons and their institutions who would like to participate in this post-market study. Please contact Mindy Carlson, Director of Clinical Research, at mindy.carlson@uocusa.com, or 612-562-0060, to inquire.
About United Orthopedic Corporation
United Orthopedic Corporation (UOC) is a leading international designer, manufacturer, and distributor of innovative, regulatory compliant orthopedic implants and instrument sets used by surgeons around the globe. UOC’s offering includes a flexible range of clinically proven solutions used to perform total hip/knee replacements and revisions, plus clinical education, service and support for surgeons and hospital staff. UOC operates Quality Management Systems (QMS) that comply with ISO 9001/13485, FDA, and CE requirements. For more information about United Orthopedic Corporation, visit www.uocusa.com.
Media Contact Erich Sandoval
Lazar Partners Ltd.
Tel: +1 917-497-2867
Email: esandoval@lazarpartners.com _________________________________
1 Heidari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Caspian Journal of Internal Medicine. 2011;2(2):205-212.
The De Angelis Group, the largest search firm dedicated solely to the orthopedic industry was named amongst the top 250 “Best Executive Recruiting Firms” listed by Forbes for 2017. The recent article was published on http://www.forbes.com on May 3, 2017, written by Jeff Kauflin.
Forbes worked with analytics firm Statista to compile a list of 4,000 executive recruiting companies. They then asked thousands of recruiters, employees who have worked with recruiting companies and H.R. managers to take an online survey, and recommend up to 10 recruiting firms (excluding their own). With over 20,000 recommendations, each company was then ranked by the highest number of recommendations.
The De Angelis Group is proud to have been named on the 2017 Forbes list and looks forward to continually working hard to bring value to the orthopedic industry. The De Angelis Group’s Managing Partner, Drue De Angelis said after receiving the news “It is an honor to be recognized for this distinction but what truly compels us is helping drive enterprise value for the companies and investors who entrust us with their most critical executive hires.”
_____
About The De Angelis Group
Founded in 2000 with one thing in mind; driving enterprise value for Orthopedic Start-up companies. The DeAngelis Group works with many of the most innovative and exciting new companies in the early stages of development to build a Talented Leadership Team.Whether your company is new to the space or you require a turn-around, our consultants first gain a solid grasp of the deliverables and the specific experience that the leader will require and then conduct the search effectively and timely. Our network in Orthopedics is vast and qualitative. We have developed algorithms to evaluate who best fits in the start-up environment and who can develop and execute a strategic plan achieving sustainable growth.
